HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target
Benzinga Newsdesk 7 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics (AMEX:PLX) with a Buy and maintains $12 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics (AMEX:PLX) with a Buy and maintains $12 price target.